Recommendations on disease management for patients with advanced human epidermal growth factor receptor 2-positive breast cancer and brain metastases: American Society of Clinical Oncology clinical practice guideline

Journal of Clinical Oncology

Volumn 32, Issue 19, 2014, Pages 2100-2108

  Ramakrishna, Naren ^a   Temin, Sarah ^d   Chandarlapaty, Sarat ^e   Crews, Jennie R ^h   Davidson, Nancy E ⁱ   Esteva, Francisco J ^f   Giordano, Sharon H ^j   Gonzalez Angulo, Ana M ^j   Kirshner, Jeffrey J ^g   Krop, Ian ^l   Levinson, Jennifer ^c   Modi, Shanu ^e   Patt, Debra A ^k   Perez, Edith A ^b   Perlmutter, Jane ^c   Winer, Eric P ^l   Lin, Nancy U ^l  

^a UNIVERSITY OF FLORIDA HEALTH   (United States)

^b MAYO CLINIC   (United States)

^c American Society of Clinical Oncology ^*

^d AMERICAN SOCIETY OF CLINICAL ONCOLOGY   (United States)

^e MEMORIAL SLOAN KETTERING CANCER CENTER   (United States)

^f NEW YORK UNIVERSITY   (United States)

^g Hematology Oncology Associates of Central New York   (United States)

^h PeaceHealth St Joseph Medical Center   (United States)

ⁱ UNIVERSITY OF PITTSBURGH CANCER INSTITUTE   (United States)

^j UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

^k TEXAS ONCOLOGY   (United States)

^l DANA FARBER CANCER INSTITUTE   (United States)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CAPECITABINE; EPIDERMAL GROWTH FACTOR RECEPTOR 2; LAPATINIB;

ADVANCED CANCER; ARTICLE; BLOOD VESSEL INJURY; BRAIN METASTASIS; BREAST CANCER; BREAST METASTASIS; CANCER GROWTH; CANCER PATIENT; CANCER PROGNOSIS; CANCER RADIOTHERAPY; CANCER SURGERY; CANCER SURVIVAL; CONSENSUS; DELPHI STUDY; EPIDERMAL GROWTH FACTOR RECEPTOR 2 POSITIVE BREAST CANCER; HUMAN; LEUKOENCEPHALOPATHY; LOCAL THERAPY; MEDICAL ONCOLOGIST; MEDICAL SOCIETY; NEUROSURGEON; ONCOLOGY; OVERALL SURVIVAL; PRACTICE GUIDELINE; PRIORITY JOURNAL; RADIATION ONCOLOGIST; STEREOTACTIC RADIOSURGERY; SYSTEMATIC REVIEW; SYSTEMIC THERAPY; TREATMENT FAILURE;

ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BRAIN NEOPLASMS; BREAST NEOPLASMS; COMORBIDITY; CONSENSUS; CRANIAL IRRADIATION; DISEASE MANAGEMENT; EVIDENCE-BASED MEDICINE; FEMALE; HEALTH STATUS DISPARITIES; HEALTHCARE DISPARITIES; HUMANS; RADIOSURGERY; RECEPTOR, ERBB-2; SOCIETIES, MEDICAL; TREATMENT OUTCOME; TUMOR MARKERS, BIOLOGICAL; UNITED STATES;

EID: 84905859056     PISSN: 0732183X     EISSN: 15277755     Source Type: Journal    
DOI: 10.1200/JCO.2013.54.0955     Document Type: Article

References (56)

1. American Society of Clinical Oncology: Breast cancer. http://www.cancer.net/cancer-types/breast-cancer
2. Bauer K, Parise C, Caggiano V: Use of ER/PR/HER2 subtypes in conjunction with the 2007 St Gallen Consensus Statement for early breast cancer. BMC Cancer 10:228, 2010
3. Vaz-Luis I, Ottesen RA, Hughes ME, et al: Impact of hormone receptor status on patterns of recurrence and clinical outcomes among patients with human epidermal growth factor-2-positive breast cancer in the National Comprehensive Cancer Network: A prospective cohort study. Breast Cancer Res 14:R129, 2012
4. Lin NU, Vanderplas A, Hughes ME, et al: Clinicopathologic features, patterns of recurrence, and survival among women with triple-negative breast cancer in the National Comprehensive Cancer Network. Cancer 118:5463-5472, 2012
5. Pestalozzi BC, Zahrieh D, Price KN, et al: Identifying breast cancer patients at risk for central nervous system (CNS) metastases in trials of the International Breast Cancer Study Group (IBCSG). Ann Oncol 17:935-944, 2006 (Pubitemid 43778983)
6. Brufsky AM, Mayer M, Rugo HS, et al: Central nervous system metastases in patients with HER2-positive metastatic breast cancer: Incidence, treatment, and survival in patients from registHER. Clin Cancer Res 17:4834-4843, 2011
7. Olson EM, Najita JS, Sohl J, et al: Clinical outcomes and treatment practice patterns of patients with HER2-positive metastatic breast cancer in the post-trastuzumab era. Breast 22:525-531, 2013
8. Pestalozzi BC, Holmes E, de Azambuja E, et al: CNS relapses in patients with HER2-positive early breast cancer who have and have not received adjuvant trastuzumab: A retrospective substudy of the HERA trial (BIG 1-01). Lancet Oncol 14:244-248, 2013
9. Hess KR, Esteva FJ: Effect of HER2 status on distant recurrence in early stage breast cancer. Breast Cancer Res Treat 137:449-455, 2013
10. Olson EM, Abdel-Rasoul M, Maly J, et al: Incidence and risk of central nervous system metastases as site of first recurrence in patients with HER2-positive breast cancer treated with adjuvant trastuzumab. Ann Oncol 24:1526-1533, 2013
11. Zimm S, Wampler GL, Stablein D, et al: Intracerebral metastases in solid-tumor patients: Natural history and results of treatment. Cancer 48:384-394, 1981 (Pubitemid 11127382)
12. Gori S, Rimondini S, De Angelis V, et al: Central nervous system metastases in HER-2 positive metastatic breast cancer patients treated with trastuzumab: Incidence, survival, and risk factors. Oncologist 12:766-773, 2007 (Pubitemid 47328220)
13. Park YH, Park MJ, Ji SH, et al: Trastuzumab treatment improves brain metastasis outcomes through control and durable prolongation of systemic extracranial disease in HER2-overexpressing breast cancer patients. Br J Cancer 100:894-900, 2009
14. Giordano SH, Temin S, Kirshner JJ, et al: Systemic therapy for patients with advanced human epidermal growth factor receptor 2-positive breast cancer: American Society of Clinical Oncology clinical practice guideline. J Clin Oncol 32:2078-2099, 2014
15. Wolff AC, Hammond ME, Hicks DG, et al: Recommendations for human epidermal growth factor receptor 2 testing in breast cancer: American Society of Clinical Oncology/College of American Pathologists clinical practice guideline update. J Clin Oncol 31:3997-4013, 2013
16. National Comprehensive Cancer Network: NCCN Clinical Practice Guidelines in Oncology: Central Nervous System Cancers (version 1.2013). http://www.nccn.org/professionals/physician-gls/f-guidelines.asp
17. Sperduto PW, Kased N, Roberge D, et al: Effect of tumor subtype on survival and the graded prognostic assessment for patients with breast cancer and brain metastases. Int J Radiat Oncol Biol Phys 82:2111-2117, 2012
18. Sperduto PW, Kased N, Roberge D, et al: The effect of tumor subtype on the time from primary diagnosis to development of brain metastases and survival in patients with breast cancer. J Neurooncol 112:467-472, 2013
19. Bendell JC, Domchek SM, Burstein HJ, et al: Central nervous system metastases in women who receive trastuzumab-based therapy for metastatic breast carcinoma. Cancer 97:2972-2977, 2003 (Pubitemid 36676250)
20. Loblaw DA, Prestrud AA, Somerfield MR, et al: American Society of Clinical Oncology clinical practice guidelines: Formal systematic review-based consensus methodology. J Clin Oncol 30:3136-3140, 2012
21. Chao JH, Phillips R, Nickson JJ: Roentgen-ray therapy of cerebral metastases. Cancer 7:682-689, 1954
22. Chang EL, Wefel JS, Hess KR, et al: Neuro-cognition in patients with brain metastases treated with radiosurgery or radiosurgery plus whole-brain irradiation: A randomised controlled trial. Lancet Oncol 10:1037-1044, 2009
23. Soffietti R, Kocher M, Abacioglu UM, et al: A European Organisation for Research and Treatment of Cancer phase III trial of adjuvant whole-brain radiotherapy versus observation in patients with one to three brain metastases from solid tumors after surgical resection or radiosurgery: Quality-of-life results. J Clin Oncol 31:65-72, 2013
24. Welzel T, Niethammer A, Mende U, et al: Diffusion tensor imaging screening of radiation-induced changes in the white matter after prophylactic cranial irradiation of patients with small cell lung cancer: First results of a prospective study. AJNR Am J Neuroradiol 29:379-383, 2008 (Pubitemid 351287900)
25. Bitzer M, Topka H: Progressive cerebral occlusive disease after radiation therapy. Stroke 26:131-136, 1995
26. Patchell RA, Tibbs PA, Regine WF, et al: Postoperative radiotherapy in the treatment of single metastases to the brain: A randomized trial. JAMA 280:1485-1489, 1998 (Pubitemid 28507400)
27. Aoyama H, Shirato H, Tago M, et al: Stereotactic radiosurgery plus whole-brain radiation therapy vs stereotactic radiosurgery alone for treatment of brain metastases: A randomized controlled trial. JAMA 295:2483-2491, 2006 (Pubitemid 43854963)
28. Kocher M, Soffietti R, Abacioglu U, et al: Adjuvant whole-brain radiotherapy versus observation after radiosurgery or surgical resection of one to three cerebral metastases: Results of the EORTC 22952-26001 study. J Clin Oncol 29:134-141, 2011
29. Bachelot T, Romieu G, Campone M, et al: Lapatinib plus capecitabine in patients with previously untreated brain metastases from HER2-positive metastatic breast cancer (LANDSCAPE): A single-group phase 2 study. Lancet Oncol 14:64-71, 2013
30. Kelly PJ, Lin NU, Claus EB, et al: Salvage stereotactic radiosurgery for breast cancer brain metastases: Outcomes and prognostic factors. Cancer 118:2014-2020, 2012
31. Karam I, Nichol A, Woods R, et al: Population-based outcomes after whole brain radiotherapy and re-irradiation in patients with metastatic breast cancer in the trastuzumab era. Radiat Oncol 6:181, 2011
32. Ammirati M, Cobbs CS, Linskey ME, et al: The role of retreatment in the management of recurrent/progressive brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96:85-96, 2010
33. Sadikov E, Bezjak A, Yi QL, et al: Value of whole brain re-irradiation for brain metastases: Single centre experience. Clin Oncol (R Coll Radiol) 19:532-538, 2007 (Pubitemid 47181189)
34. Caballero JA, Sneed PK, Lamborn KR, et al: Prognostic factors for survival in patients treated with stereotactic radiosurgery for recurrent brain metastases after prior whole brain radiotherapy. Int J Radiat Oncol Biol Phys 83:303-309, 2012
35. Tsao MN, Rades D, Wirth A, et al: Radiotherapeutic and surgical management for newly diagnosed brain metastasis(es): An American Society for Radiation Oncology evidence-based guideline. Pract Radiat Oncol 2:210-225, 2012
36. Linskey ME, Andrews DW, Asher AL, et al: The role of stereotactic radiosurgery in the management of patients with newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96:45-68, 2010
37. Kalkanis SN, Kondziolka D, Gaspar LE, et al: The role of surgical resection in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96:33-43, 2010
38. Gaspar LE, Mehta MP, Patchell RA, et al: The role of whole brain radiation therapy in the management of newly diagnosed brain metastases: A systematic review and evidence-based clinical practice guideline. J Neurooncol 96:17-32, 2010
39. American College of Radiology: ACR appropriateness criteria: Follow-up and retreatment of brain metastases. http://www.acr.org/Quality-Safety/ Appropriateness-Criteria
40. Ekenel M, Hormigo AM, Peak S, et al: Capecitabine therapy of central nervous system metastases from breast cancer. J Neurooncol 85:223-227, 2007 (Pubitemid 47629405)
41. Rivera E, Meyers C, Groves M, et al: Phase I study of capecitabine in combination with temozolomide in the treatment of patients with brain metastases from breast carcinoma. Cancer 107:1348-1354, 2006 (Pubitemid 44452785)
42. Lin NU, Diéras V, Paul D, et al: Multicenter phase II study of lapatinib in patients with brain metastases from HER2-positive breast cancer. Clin Cancer Res 15:1452-1459, 2009
43. Lin NU, Eierman W, Greil R, et al: Randomized phase II study of lapatinib plus capecitabine or lapatinib plus topotecan for patients with HER2-positive breast cancer brain metastases. J Neurooncol 105:613-620, 2011
44. Boogerd W, Dalesio O, Bais EM, et al: Response of brain metastases from breast cancer to systemic chemotherapy. Cancer 69:972-980, 1992
45. Rosner D, Nemoto T, Lane WW: Chemotherapy induces regression of brain metastases in breast carcinoma. Cancer 58:832-839, 1986 (Pubitemid 16035278)
46. Franciosi V, Cocconi G, Michiara M, et al: Front-line chemotherapy with cisplatin and etoposide for patients with brain metastases from breast carcinoma, nonsmall cell lung carcinoma, or malignant melanoma: A prospective study. Cancer 85:1599-1605, 1999 (Pubitemid 29152834)
47. Azzoli CG, Baker S Jr, Temin S, et al: American Society of Clinical Oncology clinical practice guideline update on chemotherapy for stage IV non-small-cell lung cancer. J Clin Oncol 27:6251-6266, 2009
48. Fagerlin A, Zikmund-Fisher BJ, Ubel PA: Helping patients decide: Ten steps to better risk communication. J Natl Cancer Inst 103:1436-1443, 2011
49. Butow PN, Dowsett S, Hagerty R, et al: Communicating prognosis to patients with metastatic disease: What do they really want to know? Support Care Cancer 10:161-168, 2002 (Pubitemid 36056313)
50. Hagerty RG, Butow PN, Ellis PA, et al: Cancer patient preferences for communication of prognosis in the metastatic setting. J Clin Oncol 22:1721-1730, 2004 (Pubitemid 41079812)
51. Lux MP, Bayer CM, Loehberg CR, et al: Shared decision-making in metastatic breast cancer: Discrepancy between the expected prolongation of life and treatment efficacy between patients and physicians, and influencing factors. Breast Cancer Res Treat 139:429-440, 2013
52. Mead H, Cartwright-Smith L, Jones K, et al: Racial and Ethnic Disparities in U.S. Health Care: A Chartbook. New York, NY, Commonwealth Fund, 2008
53. Howlader N, Noone AM, Krapcho M, et al (eds): SEER Cancer Statistics Review, 1975-2009 (Vintage 2009 Populations). Bethesda, MD, National Cancer Institute, 2012
54. Labonte MJ, Wilson PM, Yang D, et al: The cyclin D1 (CCND1) A870G polymorphism predicts clinical outcome to lapatinib and capecitabine in HER2-positive metastatic breast cancer. Ann Oncol 23:1455-1464, 2012
55. American Cancer Society: Cancer facts and figures for African Americans 2011-2012. http://www.cancer.org/acs/groups/content/@epidemiologysurveilance/ documents/document/acspc-027765.pdf
56. American Geriatrics Society Expert Panel on the Care of Older Adults With Multimorbidity: Patient-centered care for older adults with multiple chronic conditions: A stepwise approach from the American Geriatrics Society. J Am Geriatr Soc 60:1957-1968, 2012